Cargando…
Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma
Glioblastoma (GB) is the most common malignant brain tumor. Drug resistance frequently develops in these tumors during chemotherapy. Therefore, predicting drug response in these patients remains a major challenge in the clinic. Thus, to improve the clinical outcome, more effective and tolerable comb...
Autores principales: | Das, Arabinda, Cheng, Ron Ron, Hilbert, Megan L.T., Dixon-Moh, Yaenette N., Decandio, Michele, Vandergrift, William Alex, Banik, Naren L., Lindhorst, Scott M., Cachia, David, Varma, Abhay K., Patel, Sunil J., Giglio, Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667559/ https://www.ncbi.nlm.nih.gov/pubmed/26648752 http://dx.doi.org/10.4137/CGM.S32801 |
Ejemplares similares
-
Molecular Targets and Treatment of Meningioma
por: Miller, Rickey, et al.
Publicado: (2014) -
Current Studies of Immunotherapy on Glioblastoma
por: Agrawal, Neena Stephanie, et al.
Publicado: (2014) -
Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities
por: Das, Arabinda, et al.
Publicado: (2004) -
Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019) -
ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma
por: Marks, Eric I., et al.
Publicado: (2019)